Search published articles


Showing 4 results for Amphotericin B
In-vitro susceptibility of Aspergillus species isolated from cutaneous and visceral lesions to antifungal agents
Hashemi Sj, Zaini F, Daie R, Zibafar E, Zakeri Ma,
Volume 69, Issue 2 (5-2011)
Abstract
Background: Different studies have shown that despite the expanding number of antifungal agents, death rate caused by Aspergillus species has been increased during the recent decades due to drug-resistance occurrence, increased minimum inhibitory concentration (MIC) and cross-resistance among the isolated species. Regarding the lack of effective response to conventional treatments and antifungal susceptibility patterns of the most common isolated Aspergillus species, this study was undertaken to draw a clearer picture in the Iranian setting. Methods: During 13 months from September 2009 to October 2010, 50 clinically isolated Aspergillus cases were identified based on the method described by Klich (2002) and their morphological features. Subsequently, their susceptibility test was carried out according to NCCLS- M38A broth microdilution method. Results: We found that 7.5% of the isolated A. flavus with an MIC>2 µg/ml to amphotericin B were probably clinically resistant types, and 25% of them with an MIC<8 µg/ml to itraconazole were less sensitive isolated species. The isolates were less sensitive to voriconazole too. The MIC range of 9 strains of A. niger and the MIC of one strain of A. fumigatus had increased to all the three medications in comparison with similar foreign studies. Conclusion: In this study we found that the MICs of most isolates were in the range of the reference strains and the MICs of some isolates were in the range of similar foreign studies. In some significant cases, the MICs were beyond the known ranges showing the lower sensitivity of Iranian isolates and their increased MIC patterns.
Intralipid efficacy in decreasing Amphotericin B associated nephrotoxicity
Hasibi M, Jafari S, Khazraiyan H, Dehghan Manshadi Sa,
Volume 70, Issue 12 (3-2013)
Abstract

Background: Amphotericin B Deoxycholate (ABD) has been the best therapeutic agent for treatment of most systemic fungal infections. However, untoward adverse effects like nephrotoxicity may limit its appropriate therapeutic use. We studied administration of fat emulsion early after infusion of ABD to evaluate its effects on ABD-associated nephrotoxicity.
Methods: This study was a randomized clinical trial. Patients with fungal infections admitted in Amir-Alam and Imam-Khomeini University Hospitals, Tehran, Iran, entered the study during 1390- 1391. The patients were randomized to intervention and control groups. In both groups, patients received 1mg/kg/day ABD in dextrose 5%. In intervention arm, the patients additionally received intralipid 10% daily that was started as soon as possible within one hour after infusion of ABD. ABD-associated nephrotoxicity (a minimum 50% increase in baseline serum creatinine to a minimum of 2mg/dl), daily serum creatinine changes during first two weeks of treatment and some other relevant indices of renal function were compared between groups. ABD-related hypokalemia was also compared as an additional target.
Results: Thirty one patients entered the study. ABD-associated nephrotoxicity and values of other relevant indices of renal function were not different between intervention and control groups (P>0.05). Daily changes in serum creatinine level within first two weeks of treatment in both groups were not also statistically different (P=0.62). Furthermore, ABD-related hypokalemia was not significantly different between groups (P=0.47).
Conclusion: Administration of intralipid 10% early after infusion of ABD in dextrose 5% does not have any effect in decreasing ABD-associated nephrotoxicity. Moreover, it does not have any significant effect on ABD-related hypokalemia.


Drug susceptibility pattern of candida species isolated from skin of neonates to fluconazole, amphotericin B and caspofungin
Soraya Ghorbani , Roshanak Daie Ghazvini , Seyyed Jamal Hashemi , Parivash Kordbacheh , Ensieh Zibafar , Zahra Kamali Sarwestani, Heidar Bakhshi , Pegah Ardi ,
Volume 75, Issue 4 (7-2017)
Abstract
Background: Candida species are opportunistic yeasts that are capable of causing different infections and diseases among immunocompromised patients. Since Candida infections are major causes and frequent of septicemia in Neonatal Intensive Care Units (NICU), and they are associated with high morbidity and mortality rates, so obtaining adequate treatment seems necessary. Low birth weight preterm infants are especially vulnerable to these devastating infections. The aim of this study was to evaluate the drug susceptibility of Candida species colonized on the skin and mucous membrane of neonates to fluconazole, amphotericin B and caspofungin.
Methods: This study was carried out in the laboratory of medical mycology and serology, School of Public Health, Tehran University of Medical Sciences for the period of 7 months from June 2016 to December 2016. In this descriptive cross-sectional study, 23 isolates of Candida species including Candida parapsilosis, Candida albicans, Candida tropicalis, Candida guilliermondii and Candida krusei were studied. These under study isolates were previously isolated from skin and mucous membranes of neonates in NICU of Imam Khomeini Hospital and Children's Medical Center were identified by PCR-RFLP (Polymerase chain reaction-restriction fragment length polymorphism). Evaluation of antifungal drug susceptibility including fluconazole, amphotericin B and caspofungin was carried out. Antifungal susceptibility test was done according to the standard protocol Clinical and Laboratory Standards Institute (CLSI M27-A3) that is specific to the yeast fungi. Statistical analysis was done by using T-test in SPSS version 22 (IBM, Armonk, NY, USA) and P<0.05 was considered statistically significant.
Results: In this study, C. parapsilosis, C. albicans and C. tropicalis had the most sensitivity to fluconazole. Clinical Isolates of C. guilliermondii were also sensitive to fluconazole, but in C. krusei sensitivity was dose-dependent. All isolated species were sensitive to amphotericin B and caspofungin.
Conclusion: According to the results, all isolated Candida species were more sensitive to amphotericin B and caspofungin than other antifungal drugs. In final conclusion, Finally, it is emphasized that antifungal susceptibility testing is necessary to prevent treatment failure or recurrence of disease.

Premedication drugs’ evaluation and incidence of infusion-related reactions in patients receiving amphotericin B
Shirinsadat Badri , Sara Etemadi-Moghaddam , Azadeh Moghaddas ,
Volume 77, Issue 12 (3-2020)
Abstract
Background: Amphotericin B is one of the most useful therapeutic modalities for the treatment of patients with invasive fungal infections, in spite of serious side effects, namely kidney injury, electrolyte imbalances, and infusion-related reactions. The goal of this study was to assess the different aspects of premedication practice and the incidence and types of infusion-related reactions in patients receiving amphotericin B.
Methods: This observational study was performed on 70 hospitalized patients who received amphotericin B in different departments of two university hospitals, affiliated to Isfahan University of Medical Sciences, Isfahan, Iran, from January 2017 to February 2018. Information on physicians’ performance regarding premedication administration for amphotericin B, including the types and doses of medications administered prior to amphotericin B infusion, as well as patients’ clinical data including infusion-related side effects were collected and then analyzed in comparison with the standard practice guidelines.
Results: The study population consisted of 70 patients with the mean age of 51.6±18.3 years, who received amphotericin B for 8.2±3.5 days. From 70 evaluated patients, 21 patients (30%) had encountered the infusion-related reactions, including chills, fever, urticaria, headache, and hypotension. These side effects were evident in 19 patients (27%) who received no premedication and 2 patients (3%) who received only one drug as premedication, before amphotericin B administration. Twenty patients (28%) experienced chills, fever and headache, while 7 patients (10%) had nausea and vomiting during amphotericin B infusion. Hydrocortisone 50-200 mg, was the most prescribed agent for premedication (in 67% of patients), while chlorpheniramine 10 mg (in 50% of patients) and promethazine 10 mg (in 35% of patients) were the second and third prescribed ones, respectively.
Conclusion: In this study, the patients who received no or only one drug as premedication experienced infusion-related side effects. This emphasizes the necessity for standard premedication practices to prevent this type of adverse reactions. Considering the higher price of liposomal form of Amphotericin-B, if prescribed correctly, even the conventional form would be an effective and tolerable treatment for invasive fungal infections.

Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb